Skip to main content

Wells Fargo Tar Heel 10 miler and Fleet Feet 4+ mile run take place April 21, 2012

Chapel Hill, NC – For a second year, the Wells Fargo Tar Heel 10 miler and Fleet Feet 4+ mile run will benefit UNC Lineberger Comprehensive Cancer Center.
Runners can register online at http://tarheel10miler.com and enter the code “beatcancer5” to donate $5 per entry to cancer research and treatment in our community.

A $30 donation to the cancer center will be made for each volunteer who affiliates with UNC Lineberger.

“Thank you to Endurance Magazine for once again choosing UNC Lineberger as a charity partner,” said Shelley Earp, MD, UNC Lineberger’s director. “Our missions are aligned, we are all working to make Chapel Hill and North Carolina healthier.”

The races attracted more than 3500 runners to Chapel Hill in April 2011. Among the crowds were UNC researchers, doctors, nurses and other staff – all running a hilly course to benefit cancer research and treatment at UNC Lineberger Comprehensive Cancer Center. Overall, more than $10,000 was raised for the cancer center’s programs.

Runners wishing to raise more for UNC Lineberger should watch the cancer center’s Facebook page for more information on how to set up their own individual or team fundraising web site.

About Endurance Magazine

Endurance Magazine is the premier resource for active lifestyles in the Carolinas. Focused on educating, inspiring, and motivating athletes of all levels and abilities, Endurance Magazine offers compelling and immediately useful editorial and produces life-changing endurance events including the Wachovia Tar Heel 10 Miler and Ramblin’ Rose Women’s Triathlon Tour. For more information go to www.endurancemag.com.

About UNC Lineberger Comprehensive Cancer Center

As one of only 40 National Cancer Institute-designated comprehensive cancer centers, UNC Lineberger has brought together some of the most exceptional physicians and scientists in the country to combat cancer. The Center’s efforts span the spectrum from the laboratory to global practice, meaning that we work to understand the causes of cancer at the genetic and population levels, conduct groundbreaking laboratory research, and pioneer innovative clinical trials that bring the latest discoveries to patient bedsides. For more information, visit unclineberger.org.